Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

Halozyme Names Dr. Alison A. Armour As Senior

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Fred Kadiddlehopper Member Profile
 
Followed By 24
Posts 3,533
Boards Moderated 1
Alias Born 09/22/06
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/28/2020 9:57:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/16/2020 4:26:39 PM
Halozyme Provides 2020 Business Update And Financial Guidance PR Newswire (US) - 1/14/2020 8:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/6/2020 4:30:08 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/6/2020 4:28:55 PM
Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire (US) - 1/3/2020 8:00:00 AM
Genentech: Subcutaneous Perjeta/Herceptin Combo Comparable to IV Dow Jones News - 12/12/2019 11:44:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/18/2019 5:03:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/14/2019 6:08:17 AM
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire (US) - 11/13/2019 10:57:00 PM
Bernadette Connaughton Appointed to Syneos Health Board of Directors GlobeNewswire Inc. - 11/12/2019 4:30:00 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/12/2019 4:29:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 4:25:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:16:44 PM
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024 PR Newswire (US) - 11/12/2019 4:10:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:07:53 PM
Halozyme Reports Third Quarter 2019 Results PR Newswire (US) - 11/12/2019 4:01:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 11/5/2019 4:54:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 4:37:13 PM
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint PR Newswire (US) - 11/4/2019 7:00:00 AM
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology PR Newswire (US) - 11/4/2019 7:00:00 AM
Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 10/21/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2019 7:11:11 PM
Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire (US) - 9/23/2019 8:00:00 AM
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Usi... PR Newswire (US) - 9/13/2019 1:00:00 AM
Fred Kadiddlehopper   Monday, 05/06/19 10:03:06 AM
Re: None
Post # of 5814 
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

Halozyme Therapeutics, Inc. (NASDAQ:HALO
Monday 6 May 2019


SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice president, research and development, effective immediately. In this role, she will report to Dr. Helen Torley, president and chief executive officer.

Dr. Armour will lead Halozyme's research, clinical development, regulatory, safety and pharmacovigilance efforts. Alison's immediate focus will be the PEGPH20 regulatory submissions for pancreas cancer in the event of positive data. She will also play a key role in shaping the PEGPH20 new indication development strategy and expanding our oncology portfolio.

"I am delighted to welcome Alison to Halozyme," said Dr. Torley. "She brings a wealth of experience in all stages of oncology drug development, as well as over 15 years of practice as a clinical oncologist. Her experience and strong record of overseeing successful regulatory submissions makes Alison a valuable addition to our leadership team."

Dr. Armour joins Halozyme from Endocyte, where she served as Chief Medical Officer and was responsible for the company's clinical division, including all medical, clinical operations, regulatory, data management and pharmacovigilance activities. In this position, she worked on all aspects of the company's portfolio, including folate and PSMA and CAR-T therapies. She played a key role in Endocyte's successful in-licensing deal of PSMA617 in 2017 and the subsequent development process that resulted in Endocyte's sale to Novartis for $2.1 billion in December 2018.

Prior to joining Endocyte, Dr. Armour served as Vice President of Development and team lead for TYKERB® at GSK and then at Novartis. Earlier in her career, Dr. Armour also served as global medical science director at AstraZeneca, where she led early, late stage, and post-commercial medical development for IRESSA®, obtaining the first EGFRm+ approval in non-small cell lung cancer (NSCLS) for the drug.

"I am excited to join Halozyme and contribute to its efforts to bring innovative new therapies to the market that can improve patients' lives utilizing my experience in drug development and oncology," said Dr. Armour.

Dr. Armour is known in the industry for her research and her leadership in the areas of medical and radiation oncology—she has co-authored two textbooks and more than 60 publications. Dr. Armour earned her B.Sc. in Biochemistry, her M.B., Ch.B., M.Sc., and Doctorate of Medicine from the University of Glasgow; her FRCR at the Royal College of Radiologists London, UK and her FRCP at the Royal College of Physicians in London, UK, for contributions to the field of oncology.

About Halozyme

The more you know, the less you don't know.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist